The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Sep. 19, 8:41 AM

Slide #19. Spero Therapeutics, Inc. Secondary Offering

Company: Spero Therapeutics, Inc. (NASDAQ:SPRO)
Date announced: 9/9/2020
Shares Offered: 8,000,000
Secondary Offering Details: Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock in the aggregate, consisting of an offering of shares of common stock (the "common stock offering") and shares of non-voting Series D Convertible Preferred Stock with each share of Series D Convertible Preferred Stock being convertible into 1,000 shares of common stock. All of the securities in the offering will be sold by Spero. In addition, Spero expects to grant the underwriters in the common stock offering a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discounts and commissions.

Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments involving multi-drug resistant (MDR), bacterial infections and rare diseases. Co.'s product candidate, Tebipenem Pivoxil Hydrobromide, is designed to be oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Co. is developing SPR720, an oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections. Co.'s platform, Potentiator Platform, that includes an IV-administered product candidate, SPR206 to treat MDR Gram-negative infection in the hospital.

SPRO SEC Filing Email Alerts Service

Open the SPRO Page at The Online Investor »

Company Name: 
Spero Therapeutics Inc
Website: 
www.sperotherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding SPRO: 
15
Total Market Value Held by ETFs: 
$11.86M
Total Market Capitalization: 
$211.00M
% of Market Cap. Held by ETFs: 
5.62%
 

Open the SPRO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
61st percentile
(ranked higher than approx. 61% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.